Results 181 to 190 of about 5,057,415 (322)

Corrigendum: Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy

Frontiers in Pharmacology, 2021
Yihui Zhou, Xiaomeng Gao, Meng Yuan, Bo Yang, Bo Yang, Qiaojun He, Qiaojun He, Qiaojun He, Ji Cao, Ji Cao, Ji Cao   +10 more
doaj   +1 more source

IMIDAZO-1,2,3-TRIAZINES AS SUBSTRATES AND INHIBITORS FOR XANTHINE OXIDASE

, 1952
Elliott Shaw, D. W. Woolley
openalex   +1 more source

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Journal of the American College of Cardiology, 2018
Syed S Mahmood, M. Fradley, J. Cohen, A. Nohria, K. Reynolds, L. Heinzerling, R. Sullivan, Rongras Damrongwatanasuk, Carol L Chen, Dipti Gupta, M. Kirchberger, Magid Awadalla, Malek Z O Hassan, J. Moslehi, Sachin P. Shah, Sarju Ganatra, P. Thavendiranathan, D. Lawrence, J. Groarke, T. Neilan   +19 more
semanticscholar   +1 more source

Respiratory complex I‐mediated NAD+ regeneration regulates cancer cell proliferation through the transcriptional and translational control of p21Cip1 expression by SIRT3 and SIRT7

Molecular Oncology, EarlyView.
NAD+ regeneration by mitochondrial complex I NADH dehydrogenase is important for cancer cell proliferation. Specifically, NAD+ is necessary for the activities of NAD+‐dependent deacetylases SIRT3 and SIRT7, which suppress the expression of p21Cip1 cyclin‐dependent kinase inhibitor, an antiproliferative molecule, at the translational and transcriptional
Masato Higurashi, Kazunori Mori, Hidetsugu Nakagawa, Momoko Uchida, Fumihiro Ishikawa, Motoko Shibanuma   +5 more
wiley   +1 more source

TISSUE HEMOLYSINS AS LYSIN-INHIBITOR COMPLEXES [PDF]

, 1951
Eric Ponder
openalex   +1 more source

Immune-related adverse events of checkpoint inhibitors

Nature Reviews Disease Primers, 2020
M. Ramos-Casals, J. Brahmer, M. Callahan, A. Flores-Chávez, N. Keegan, M. Khamashta, O. Lambotte, X. Mariette, A. Prat, M. Suarez‐Almazor   +9 more
semanticscholar   +1 more source

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

Molecular Oncology, EarlyView.
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen, Cara Ellen Wogsland, Emmet McCormack, Johanna Mäenpää, Kristine Madsen, Karen Stampe Petersson, Mansoor Raza Mirza, Line Bjørge   +11 more
wiley   +1 more source

Further Studies with Xanthine Oxidase Inhibitors

, 1959
W.W. Westerfeld, Dan A. Richert, Edwin S. Higgins   +2 more
openalex   +1 more source

Protease inhibitors. 2. Bacterial proteases and their inhibitors [PDF]

, 1949
E. S. Duthie, L. Lorenz
openalex   +1 more source

Circulating citrate as a mediator in the relationship between HMGCR inhibitors and chronic hepatitis B: a Mendelian randomization study. [PDF]

Sci Rep
Zhang L, Li Y, Li Y.
europepmc   +1 more source